Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Update on SAS progress on transformation plan

When Q1 results were released on February 22, SAS announced a new comprehensive business transformation plan; SAS FORWARD, which is designed to secure long-term competitiveness and improved financial strength. As outlined at that time, the success of the SAS FORWARD Plan is entirely dependent upon an ability to deleverage SAS and raise significant amounts of new equity capital. Both are directly dependent upon SAS management and its key stakeholders working together to deliver by FY2026 a full SEK 7.5 billion in annual cost reductions (inclusive of interest expense and dividends on hybrid

Bulletin from Bactiguard Holding AB’s (publ) Annual General Meeting

At Bactiguard Holding AB’s (publ) Annual General Meeting (AGM) on 29 April 2022, the following resolutions were made:The AGM adopted the income statements and balance sheets for 2021 and decided that no dividend for the financial year 2021 will be paid. Retained earnings and the company's result for the year will be carried forward. The Board of Directors and CEOs were discharged from liability for their administration of the company for the financial year 2021. The AGM resolved that the remuneration until the next AGM shall be paid in an amount of SEK 750 000 respectively to the

Nel ASA: Nel joins network of Norwegian technology companies

(Oslo, 29. April, 2022) Nel ASA (Nel, OSE:NEL) joins network of Norwegian technology companies with international growth ambitions. The purpose of the network, which is named Nordic Industry Center, is to create an arena for knowledge sharing, project development, and acceleration of Norwegian companies that want to take part in Chinese mega projects and grow their business in China. Nordic Industry Center is initiated by BI Norwegian Business School and Kongsberg Innovation and located at the Tsinghua University in Beijing, China’s leading University. Nel entered into a cooperation

Nordic Aqua Partners A/S (NOAP): Considerations to relocate to Norway

Nordic Aqua Partners A/S ("NOAP") is incorporated as a Danish limited liability company, but listed on Euronext Growth Oslo. The Board of Directors of NOAP is considering to propose to transfer the jurisdiction of incorporation of NOAP from Denmark to Norway. In the assessment of the Board of Directors, the current company structure is not ideal, and the Board of Directors is of the opinion that it will be more efficient and investor friendly if NOAP is incorporated in the jurisdiction of the multilateral trading facility on which its shares are listed.  The Board of Directors is

Catena begins next step in Logistics Position Landvetter and signs agreement with MM-Sport

Catena has signed an agreement with MM-Sport for the construction and rental of a new logistics facility at Logistics Position Landvetter in Härryda municipality near Gothenburg. The building is expected to be complete in 2024 and the total investment is anticipated to cost SEK 449 million29 April 2022, 11:30 a.m. CEST In connection with the detailed development plan in effect from December 2021, Catena signed a land transfer agreement concerning part of the Dansered 1:64 property. The surface area of the land covers 210,000 sq m in a top logistical location alongside route 40 by

NoHo Partners Plc's Q1/2022 Interim Report briefing on 10 May 2022 at 10 a.m. at Vanha Ylioppilastalo

NoHo Partners Plc INVESTOR NEWS 29 April 2022 at 12:30 NoHo Partners Plc's Q1/2022 Interim Report briefing on 10 May 2022 at 10 a.m. at Vanha Ylioppilastalo NoHo Partners Plc will publish its Interim Report for January 1 – March 31, 2022 on Tuesday, 10 May 2022 approximately at 8:15 a.m. Finnish time, after which the Interim Report is available at www.noho.fi. A briefing for the media, analysts and investors will be organized on the same day at 10:00 a.m. at Vanha Ylioppilastalo, Mannerheimintie 3, 00100 Helsinki. The presentation about NoHo Partners Plc's Q1/2022 financial

SLP acquires property and starts construction in Södertälje

The real estate company SLP has today acquired and taken possession of the property Tveta-Valsta 4:9 in Södertälje municipality. The property will be developed with a logistics building with an estimated occupancy in the first quarter of 2023 of a total of approximately 6,500 sqm. Alfa Quality Moving AB is the tenant and leases the entire logistics property until 31 January 2035 and the base rent amounts to approximately SEK 6.8 million. The property offers the possibility of further development of approximately 5,000 sqm. The seller is Ätteläggen Invest AB.“With the building permit

SRBNK: SpareBank 1 SR-Bank - Supervisory Review and Evaluation Process (SREP)

The Financial Supervisory Authority of Norway ("the FSA") regularly carries out a Supervisory Review and Evaluation Process,  "SREP", where they evaluate SpareBank 1 SR-Bank ASA’s risks and capital needs. The SREP includes a decision regarding the Pillar 2 Requirement and the Pillar 2 Guidance. SpareBank 1 SR-Bank ASA has now received this year's decision from the FSA. The Requirement is meant to cover risks which the bank is exposed to, and which is not, or only partially, covered by the Pillar 1 regulation. The Pillar 2 Requirement must be met with common equity tier 1 (CET1) capital.

Change in number of shares and votes in Episurf Medical

Episurf Medical AB (NASDAQ: EPIS B): On behalf of shareholders in Episurf Medical AB, conversion of class A-shares to B-shares were carried out during April in accordance with the Articles of Association. Through the conversions, the number of A-shares has decreased by 318,537, and the number of B-shares has increased by the same amount. The total number of shares amounts to 266,539,986, of which 479,357 are A-shares and 266,060,629 are B-shares. The total number of votes after the conversions amounts to 267,498,700.

Enersense International Plc’s January-March 2022 Business Review: Result improved significantly – successful corporate transactions in green energy

Enersense International PlcStock Exchange Release 29 April 2022 at 12:00 p.m.This release is a summary of Enersense International Plc’s January-March 2022 Business Review. Thecomplete report is attached to this release as a pdf file. It is also available on the company’s website at www.enersense.com/investors.  January–March 2022 • Revenue EUR 53.8 million (53.3), 0.9% year-on-year • EBITDA EUR 5.4 million (1.7), EBITDA margin 10.1% (3.2) • Operating profit EUR 3.2 million (-0.6), profit margin 6.0% (-1.2) • The order backlog stood at EUR 295,5 million (309,0) at the

Tele2 steps up collaboration with Reach for Change

Stockholm – Tele2 AB (“Tele2”) (Nasdaq Stockholm: TEL2 A and TEL2 B) has for more than 10 years worked together with Reach for Change to make life better for 4.3 million children and young people by supporting social entrepreneurs and their activities. This collaboration is now being expanded in line with Tele2's ambition to lead in sustainability and Reach for Change's global goal of reaching 30 million children and young people by 2030.– To achieve the Agenda 2030 goals we need to strive for change across all sectors. We believe that Tele2 can make a bigger difference by deepening our

Solwers Plc - Managers' Transactions

Solwers Plc Company release 29 April 2022 at 12:00 EEST Solwers Oyj - Managers' Transactions____________________________________________Person subject to the notification requirementName: John LindahlPosition: Member of the Board/Deputy member Issuer: Solwers OyjLEI: 7437002BMPCI7Q5PN611Notification type: INITIAL NOTIFICATIONReference number: 13224/4/4____________________________________________ Transaction date: 2022-04-29Venue: FIRST NORTH GROWTH MARKET FINLAND (FSME)Instrument type: SHAREISIN: FI4000452545Nature of the transaction: ACQUISITION

World Shipping Council welcomes EU Parliament Transport Committee Opinion on the EU ETS

Brussels, 29 April 2022 – On April 28[th], the MEPs serving on the TRAN Committee voted to adopt their opinion and proposed amendments as input to the European Parliament’s consideration of the EU ETS revision.Regulation to include shipping in the EU ETS is under development as part of the EU Green Deal, a great opportunity for the EU to contribute to the transition to zero carbon for international shipping. The European Commission proposal is now under review by the European Parliament, with the EP ENVI Committee holding the lead rapporteur role and EP TRAN Committee providing input guided

Summary from Annual Report 2021: Brain+ (BRAINP) is ahead of its IPO plan

“We are dedicated to helping people with dementia and Alzheimer’s disease – their families and their caregivers – through the use of our unique Digital Therapeutic software solutions that are being developed and validated through rigorous scientific and clinical trials. 2021 brought us closer to this core objective and we are now in a strong position to launch our first dementia product in 2023, 2 years ahead of plan. This will be a highly important commercial first step towards leadership in an emerging US billion-dollar market”, said Kim Baden-Kristensen, CEO of Brain+.The following is a

Annual Report 2021 for Brain+ A/S

Brain+ annual report for 2021 is now available on the Company´s websiteThe annual report including the auditor’s report is available as an attached file and can also be read on the Company's website at https://www.brain-plus.com/ Contact Information CEO, Kim Baden-Kristensen + 45 31393319, E-mail: kim@brain-plus.com, Brain+ A/S, Købmagergade 53, 3. Certified Advisor: Keswick Global AG, + 43 1 740 408045 , E-mail: info@keswickglobal.com ( info@keswickglobal.com) About BRAIN+ [BRAINP] The mission of Brain+ is to restore patients’ independence and quality of life by treating and

Norse Atlantic Airways launches ticket sales between Norway and the United States with one-way fares starting from NOK 995 and $129

Today, Norse Atlantic Airways has opened ticket sales for flights between Norway and the United States with the full launch of www.flynorse.com. This marks a milestone for the company and heralds a new era for consumers seeking good value, choice and friendly service when choosing to travel across the Atlantic.Fares will start from an unprecedented NOK 995 and $129 one-way, including all applicable taxes. The first flight departing from Oslo to New York (JFK) will take place on 14th June. The airline will also serve Fort Lauderdale (FLL), Orlando (MCO) and Los Angeles (LAX) from Oslo.  “

Change in number of shares and votes in Beijer Electronics Group

The total number of shares in Beijer Electronics Group AB as per April 29, 2022 amounts to 29,051,688, divided into 28,768,324 ordinary shares and 283,364 class C shares, corresponding to a total of 28,796,660.4 votes.The increased number of shares and votes is due to a new share issue of 99,750 class C shares within the company’s incentive program LTI 2021/2024. The company holds all class C shares. The shares are intended to be used for hedging of obligations under the incentive program.

BioStock: Elicera continues to deliver proof-of-concept data

Swedish cell and gene therapy company Elicera Therapeutics has achieved preclinical proof-of-concept in two of its immuno-oncology projects. iTANK, a universal CAR T-cell enhancement technology platform, reached proo-of-concept late last year, and the data was published in a high impact journal earlier this month.  Most recently, Elicera announced concluding proof-of-concept studies with ELC-201, a next-generation oncolytic virus aimed at treating a wide range of tumour indications.Read the article at biostock.se: https://www.biostock.se/en/2022/04/elicera-continues-to-deliver-proof-of-

BioStock: Pila Pharma takes XEN-D0501 into pain management

After focusing solely on diabetes as a development track for candidate XEN-D0501, Pila Pharma is now taking the next step of its journey filing an application for Orphan Drug Designation in the U.S. If this is approved, it will allow the company to expand its pipeline by adding a new indication. BioStock contacted CEO Dorte X. Gram to find out more about the venture and first quarter of the year.Read the full article at biostock.se:https://www.biostock.se/en/2022/04/pila-pharma-takes-xen-d0501-into-pain-management/This is a press release from BioStock - Connecting Innovation & Capital.

Number of shares and votes in Calliditas Therapeutics

During April, Calliditas Therapeutics AB (publ) has allotted 830,586 common shares within the company’s warrant program issued in 2018. Thus, as of April 29, 2022, the number of shares and votes in the company amounts to 53,172,170. For further information, please contact: Mikael Widell, Investor relations Tel.: +46 703 11 99 60, email: mikael.widell@calliditas.com The information in the press release is such that Calliditas Therapeutics AB (publ) is required to disclose pursuant to the Swedish Financial Instruments Trading Act. The information was submitted for publication,

Terveystalo’s subsidiary Feelgood acquires Jobbhälsan i Norr

Press release 29 April 2022 at 11:00 EEST   Terveystalo’s subsidiary Feelgood Svenska AB has today signed an agreement to acquire Jobbhälsan i Norr AB, a strong player in occupational health in Piteå, Sweden. The acquisition is part of Feelgood's growth strategy and strengthens its position in Norrbotten region as a leading health company for today’s working life.   “A central part of our strategy is to strengthen our local presence in important markets. Norrbotten is a region with strong economic growth and Jobbhälsan i Norr has a good reputation and some well-known, large

Dicot presenting on Aktiedagen in Stockholm

Press release: Uppsala, April 29, 2022. On Monday May 2, CEO Elin Trampe will be on the Opera Terrace stage presenting Dicot during the event Aktiedagen Stockholm.Dicot's CEO Elin Trampe will give her presentation at 09:00 on Monday May 2, where she will talk about the future for the company's potency drug development and the results achieved so far. Aktiedagen Stockholm is a hybrid event arranged by Aktiespararna that both takes place physically on the Opera Terrace and is broadcasted live via YouTube. To register for the event, please go here: Registrering Aktiedagen Stockholm 

Diamyd® meta-analysis is now available as Open Access publication

An updated large-scale Diamyd[®] meta-analysis, recently published in the peer-reviewed scientific journal Diabetes, Obesity and Metabolism, is now freely available as Open Access. The published analysis, first announced on April 20, 2022, that supports the efficacy of the therapeutic diabetes vaccine Diamyd[®][ ]in individuals recently diagnosed with Type 1 Diabetes carrying the genetic HLA DR3-DQ2 haplotype, can be accessed for free at https://doi.org/10.1111/dom.14720 About Diamyd MedicalDiamyd Medical develops precision medicine therapies for type 1 diabetes. The diabetes

There are no items matching the current filter
There are no more items matching the current filter
Back to top